Jabbour Jerome D

SEC source: 0001493152-26-008330 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-02-26

F1 · derivative.exercise_date: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.

SEC source: 0001641172-25-008424 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,100

Underlying: Common Stock · 70,100 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026.

SEC source: 0001493152-23-045170 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,500,000

Underlying: Common Stock · 3,500,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-22-036236 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,988,300

Underlying: Common Stock · 1,988,300 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0000905718-21-001615 · matinas_fm4dec142021.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,658,100

Underlying: Common Stock · 1,658,100 shares

Expires 2031-12-13

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.

SEC source: 0000905718-21-000830 · matinasbio_fm4jun192021.xml · derivative · entry 3

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000830 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 840,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.

SEC source: 0000905718-21-000830 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,011

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-21-000133 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600,000

Underlying: Common Stock · 1,600,000 shares

Expires 2030-12-31

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022.

SEC source: 0001493152-20-011763 · ownership.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 804,011

F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-20-011536 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone.

SEC source: 0001493152-20-004195 · ownership.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 799,511

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.64 to $0.65, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001493152-20-000116 · ownership.xml · derivative · entry 2

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2030-01-01

F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021.

SEC source: 0000905718-19-000721 · matinasbio_fm4aug192019.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 786,511

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.6785 to $0.6990, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001493152-20-000116 · ownership.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 789,511

F1 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-19-009099 · ownership.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 771,861

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7929 to $0.8025, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0000905718-19-000110 · jabbour-matinasfm4_feb112019.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2029-02-10

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-18-000584 · jabbour-matinasfm4_jun2118.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · derivative.exercise_date: On June 21, 2018, the Reporting Person purchased 15 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F1 · derivative.expiration_date: On June 21, 2018, the Reporting Person purchased 15 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

SEC source: 0000905718-18-000324 · matinasbiophfm4_mar2218.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2028-03-21

F1 · derivative.exercise_date: 25% of the shares vest on March 22, 2019 and the remaining shares vest in equal monthly installments over the next 36 months.

F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 379,687 shares of issuer's common stock to his ex-wife pursuant to a domestic relations order and he transferred the economic benefits of employee stock options to purchase an aggregate of 612,500 shares with exercise prices ranging from $0.41 to $1.28 per share to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife.